{"protocolSection": {"identificationModule": {"nctId": "NCT01814748", "orgStudyIdInfo": {"id": "3102-028"}, "secondaryIdInfos": [{"id": "2012-004303-12", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in \u226518 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)", "officialTitle": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in \u226518 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-09-14", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09-14", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-03-18", "studyFirstSubmitQcDate": "2013-03-18", "studyFirstPostDateStruct": {"date": "2013-03-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-06-07", "resultsFirstSubmitQcDate": "2016-06-07", "resultsFirstPostDateStruct": {"date": "2016-07-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-09", "lastUpdatePostDateStruct": {"date": "2018-09-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will examine the safety and efficacy of once-weekly omarigliptin in participants 18 to \\<45 years of age with Type 2 diabetes mellitus and inadequate glycemic control. The study hypothesis is that treatment with omarigliptin compared with placebo provides greater reduction in hemoglobin A1c (A1C) in participants after 24 weeks."}, "conditionsModule": {"conditions": ["Diabetes Mellitus"], "keywords": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Metformin", "Hypoglycemic Agents", "Pharmacologic Actions", "Therapeutic Uses"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 203, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omarigliptin 25 mg", "type": "EXPERIMENTAL", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.", "interventionNames": ["Drug: Omarigliptin", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.", "interventionNames": ["Drug: Placebo to omarigliptin", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Omarigliptin", "description": "Omarigliptin 25 mg capsule administered orally once weekly", "armGroupLabels": ["Omarigliptin 25 mg"], "otherNames": ["MK-3102"]}, {"type": "DRUG", "name": "Placebo to omarigliptin", "description": "Matching placebo to omarigliptin 25 mg capsule administered orally once weekly", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.", "armGroupLabels": ["Omarigliptin 25 mg", "Placebo"], "otherNames": ["Fortamet\u00ae", "Glucophage\u00ae", "Glucophage\u00ae XR", "Glumetza\u00ae", "Riomet\u00ae", "Metgluco\u00ae", "Glycoran\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 24", "description": "A1C (%) is used to report average blood glucose levels over prolonged periods of time.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event (AE)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Data presented exclude data following the initiation of glycemic rescue.\n\nThe safety database was analyzed in a standard fashion in the all participants as treated (APaT) population for all participants who took at least one dose of study medication. This analysis may have been confounded by the use of metformin prohibited by the protocol (see efficacy results description above).", "timeFrame": "Up to Week 27"}, {"measure": "Percentage of Participants Who Discontinued Study Drug Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Data presented exclude data following the initiation of glycemic rescue.\n\nThe safety database was analyzed in a standard fashion in the APaT population for all participants who took at least one dose of study medication. This analysis may have been confounded by the use of metformin prohibited by the protocol (see efficacy results description above).", "timeFrame": "Up to Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-hr PMG at Week 24", "description": "Blood glucose was measured 120 minutes from start of meal.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change in Baseline in FPG at Week 24", "description": "Blood glucose was measured on a fasting basis.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "timeFrame": "Baseline and Week 24"}, {"measure": "Percentage of Participants Attaining A1C Glycemic Goals of <7.0% at Week 24", "description": "Percentage of participants was estimated using standard multiple imputation techniques (constrained longitudinal data analysis \\[cLDA\\] model). Within-group confidence intervals (CIs) were calculated via the Wilson score method.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Attaining A1C Glycemic Goals of <6.5% (48 mmol/Mol) at Week 24", "description": "Percentage of participants was estimated using standard multiple imputation techniques (cLDA). Within-group CIs were calculated via the Wilson score method.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Who Required Glycemic Rescue by Week 24", "description": "Participants exceeding pre-specified glycemic thresholds after starting the double-blind treatment period may have received rescue therapy (per protocol) with open-label metformin initiated by the investigator.\n\nThis analysis may have been confounded by the use of metformin prohibited by the protocol (see efficacy results description above).", "timeFrame": "Up to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has type 2 diabetes mellitus\n* Currently not on an antihyperglycemic agent (AHA) for at least the past 12 weeks and has not been treated with omarigliptin at any time prior to study participation\n* Participant is one of the following:\n\n  1. Male\n  2. Female who is not of reproductive potential\n  3. Female of reproductive potential who agrees to remain abstinent from heterosexual activity or use (or have her partner use) 2 acceptable methods of contraception to prevent pregnancy during the study and for 21 days after the last dose of study drug\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* History of hypersensitivity to dipeptidyl-peptidase-4 (DPP-4) inhibitor\n* Currently participating in or has participated in a clinical trial in the past 12 weeks\n* Is on a weight loss program and not in the maintenance phase; has been on a weight loss medication in the past 6 months; or has undergone bariatric surgery within 12 months prior to study participation\n* Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study\n* Is on or likely to require treatment for \u226514 consecutive days or repeated courses of pharmacologic doses of corticosteroids\n* Is currently being treated for hyperthyroidism or is on thyroid replacement therapy and has not been on a stable dose for at least 6 weeks\n* Is expecting to undergo hormonal therapy in preparation to donate eggs during the study, including 21 days following the last dose of study drug\n* History of active liver disease (other than non-alcoholic hepatic steatosis) including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease\n* Has human immunodeficiency virus (HIV)\n* Has had new or worsening coronary heart disease or congestive heart failure within the past 3 months, or has any of the following disorders within the past 3 months:\n\n  1. Acute coronary syndrome\n  2. Coronary artery intervention\n  3. Stroke or transient ischemic neurological disorder\n* Has poorly controlled hypertension\n* History of malignancy \u22645 years prior to study participation, except for basal cell or squamous cell skin cancer or in situ cervical cancer\n* Has a hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n* Has a positive urine pregnancy test\n* Pregnant or breastfeeding, or is expecting to conceive during the study, including 21 days following the last dose of study drug\n* User of recreational or illicit drugs or has had a recent history of drug abuse. Routinely consumes \\>2 alcoholic drinks per day or \\>14 alcoholic drinks per week, or engages in binge drinking.\n* Has donated blood products or has had a phlebotomy (\\>300 mL) within 8 weeks of study participation, or intends to donate blood products during the study or has received, or is anticipated to receive, blood products within 12 weeks of study participation or during the study\n* Has a clinically significant electrocardiogram abnormality", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "44 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "28923291", "type": "DERIVED", "citation": "Gantz I, Sokolova L, Jain L, Iredale C, O'Neill EA, Wei Z, Lam R, Suryawanshi S, Kaufman KD, Engel SS, Lai E. Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds. Clin Ther. 2017 Oct;39(10):2024-2037. doi: 10.1016/j.clinthera.2017.08.009. Epub 2017 Sep 18."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "FG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "102"}, {"groupId": "FG001", "numSubjects": "101"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "94"}, {"groupId": "FG001", "numSubjects": "94"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Study site terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "BG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "101"}, {"groupId": "BG002", "value": "203"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.8", "spread": "4.7"}, {"groupId": "BG001", "value": "39.5", "spread": "4.5"}, {"groupId": "BG002", "value": "39.2", "spread": "4.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "76"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "127"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.9", "spread": "0.8"}, {"groupId": "BG001", "value": "8.1", "spread": "0.9"}, {"groupId": "BG002", "value": "8.0", "spread": "0.8"}]}]}]}, {"title": "2-hour post-meal glucose (2-hr PMG)", "description": "Participants with available data at baseline: Omarigliptin, n=98; Placebo, n=101; Total, n=199", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "204.9", "spread": "55.1"}, {"groupId": "BG001", "value": "217.3", "spread": "67.7"}, {"groupId": "BG002", "value": "211.2", "spread": "62.0"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "164.0", "spread": "38.9"}, {"groupId": "BG001", "value": "167.8", "spread": "40.6"}, {"groupId": "BG002", "value": "165.9", "spread": "39.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 24", "description": "A1C (%) is used to report average blood glucose levels over prolonged periods of time.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "populationDescription": "Full analysis set (FAS) population comprised all participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "lowerLimit": "-0.60", "upperLimit": "-0.06"}, {"groupId": "OG001", "value": "-0.45", "lowerLimit": "-0.72", "upperLimit": "-0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.535", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Terms for treatment, time, and the interaction of time by treatment, with the constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.26", "ciUpperLimit": "0.49"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event (AE)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Data presented exclude data following the initiation of glycemic rescue.\n\nThe safety database was analyzed in a standard fashion in the all participants as treated (APaT) population for all participants who took at least one dose of study medication. This analysis may have been confounded by the use of metformin prohibited by the protocol (see efficacy results description above).", "populationDescription": "APaT population included all randomized participants who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 27", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "39.2"}, {"groupId": "OG001", "value": "39.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.8", "ciUpperLimit": "13.0"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Drug Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Data presented exclude data following the initiation of glycemic rescue.\n\nThe safety database was analyzed in a standard fashion in the APaT population for all participants who took at least one dose of study medication. This analysis may have been confounded by the use of metformin prohibited by the protocol (see efficacy results description above).", "populationDescription": "APaT population included all randomized participants who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "2.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-2.0"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hr PMG at Week 24", "description": "Blood glucose was measured 120 minutes from start of meal.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "populationDescription": "FAS population comprised all participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.3", "lowerLimit": "-26.1", "upperLimit": "3.5"}, {"groupId": "OG001", "value": "-15.5", "lowerLimit": "-30.6", "upperLimit": "-0.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.685", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Terms for treatment, time, and the interaction of time by treatment, with the constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "4.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.1", "ciUpperLimit": "24.4"}]}, {"type": "SECONDARY", "title": "Change in Baseline in FPG at Week 24", "description": "Blood glucose was measured on a fasting basis.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "populationDescription": "FAS population comprised all participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.0", "lowerLimit": "-14.6", "upperLimit": "4.6"}, {"groupId": "OG001", "value": "-1.3", "lowerLimit": "-11.2", "upperLimit": "8.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.586", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Terms for treatment, time, and the interaction of time by treatment, with the constraint that the mean baseline is the same for all treatment groups.", "paramType": "Difference in least squares means", "paramValue": "-3.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.1", "ciUpperLimit": "9.7"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Attaining A1C Glycemic Goals of <7.0% at Week 24", "description": "Percentage of participants was estimated using standard multiple imputation techniques (constrained longitudinal data analysis \\[cLDA\\] model). Within-group confidence intervals (CIs) were calculated via the Wilson score method.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "populationDescription": "FAS population comprised all participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.5", "lowerLimit": "24.7", "upperLimit": "43.7"}, {"groupId": "OG001", "value": "34.0", "lowerLimit": "25.1", "upperLimit": "44.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Mietinnen and Nurminen", "paramType": "Between-group rate difference", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.0", "ciUpperLimit": "13.1"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Attaining A1C Glycemic Goals of <6.5% (48 mmol/Mol) at Week 24", "description": "Percentage of participants was estimated using standard multiple imputation techniques (cLDA). Within-group CIs were calculated via the Wilson score method.\n\nThe unexpected absence of a treatment effect in this study led to investigations that included measurement of metformin levels in available samples collected for future research during the study. Of the 92 participants with samples who had not been rescued with metformin, 57% (25/44) in the placebo group and 29% (14/48) in the omarigliptin group had detectable metformin, indicating the use of metformin that was prohibited by the protocol. The use of metformin prohibited by the protocol was without investigator knowledge and is a confounding factor impacting the ability to draw any conclusions regarding the efficacy results from this study.", "populationDescription": "FAS population comprised all participants who received at least one dose of study treatment and had a baseline measurement or a post-randomization measurement for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.7", "lowerLimit": "14.5", "upperLimit": "31.1"}, {"groupId": "OG001", "value": "17.6", "lowerLimit": "11.3", "upperLimit": "26.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Mietinnen and Nurminen", "paramType": "Between-group rate difference", "paramValue": "4.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.4", "ciUpperLimit": "15.5"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Required Glycemic Rescue by Week 24", "description": "Participants exceeding pre-specified glycemic thresholds after starting the double-blind treatment period may have received rescue therapy (per protocol) with open-label metformin initiated by the investigator.\n\nThis analysis may have been confounded by the use of metformin prohibited by the protocol (see efficacy results description above).", "populationDescription": "All randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 24", "groups": [{"id": "OG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}, {"id": "OG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.8"}, {"groupId": "OG001", "value": "12.9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 27 weeks; Serious adverse events (SAEs) were collected up to 24 weeks during treatment + 3 week follow-up, non-serious adverse events (NSAEs) were collected up to 24 weeks during treatment", "description": "SAEs include data after glycemic rescue; NSAEs exclude data after glycemic rescue. Investigations performed by the Sponsor revealed that many participants had used a prohibited antihyperglycemic agent-metformin (i.e., not as rescue medication; see efficacy results description above).", "eventGroups": [{"id": "EG000", "title": "Omarigliptin 25 mg", "description": "Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.", "seriousNumAffected": 1, "seriousNumAtRisk": 102, "otherNumAffected": 10, "otherNumAtRisk": 102}, {"id": "EG001", "title": "Placebo", "description": "Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.", "seriousNumAffected": 3, "seriousNumAtRisk": 101, "otherNumAffected": 7, "otherNumAtRisk": 101}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}, {"term": "Vulvovaginal candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 101}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 101}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Investigations indicate that the presence of metformin in future biomedical research (FBR) samples from non-rescued participants was due to participant self-administration of metformin outside of the protocol and without investigator knowledge."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Mexico", "Romania", "Russian Federation", "Serbia", "South Africa", "Ukraine", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}